Press Releases
Sep 24, 2024
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma

- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing...

Sep 20, 2024
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

- Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2 -...

Sep 18, 2024
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure

- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring - TOKYO, Sept. 18, 2024 /PRNewswire/ --...

EXPLORE ALL US PRESS RELEASES

Articles
Jul 18, 2024
Astellas Legal and IP Division Takes Action to Advance Diversity, Equity and Inclusion

Diversity, equity and inclusion (DEI) have always been critically important to the Astellas Legal and IP Division. Since 2017, the Astellas Legal and IP Division has actively worked to promote DEI...

Feb 8, 2024
From Recurrence to Perseverance: Jim's Prostate Cancer Story

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023
Astellas Recognized for its Support of the LGBTQ+ Community through Human Rights Campaign Foundation’s Annual Corporate Equality Index

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products